ArticleOxford medical case reports2025
Newly diagnosed T-large granular lymphocyte Leukemia presenting with severe neutropenia: a case report.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-large granular lymphocyte leukemia (T-LGLL) is an uncommon chronic lymphoproliferative syndrome marked by clonal proliferation of cytotoxic (CD8+) T cells. It is usually characterized by cytopenia, particularly neutropenia, and may be associated with autoimmune disease. We report a case of a 56-year-old Moroccan female patient presenting with a 2-month history of dry eye syndrome, asthenia, and severe neutropenia. Initial investigations revealed lymphocytosis, and the peripheral blood smear revealed approximately 13% of large granular lymphocytes. Flow cytometry confirmed T-LGLL with a CD3+, CD8+, CD57+ phenotype. First-line treatment with low-dose methotrexate yielded no improvement after six months. The patient was then successfully treated with oral cyclophosphamide, with normalization of neutrophil and hemoglobin levels, and resolution of sicca symptoms. This case highlights the importance of early diagnosis and tailored immunosuppressive therapy in managing T-LGLL, particularly in patients with severe neutropenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.